{Reference Type}: Journal Article
{Title}: Osteoporosis, bisphosphonates, and ocular inflammation.
{Author}: Nouraeinejad A;
{Journal}: Eur J Ophthalmol
{Volume}: 0
{Issue}: 0
{Year}: Sep 2022 4
{Factor}: 1.922
{DOI}: 10.1177/11206721221125022
{Abstract}: BACKGROUND: Osteoporosis, as a musculoskeletal disease, is very common, especially in the era of aging society. It is described by a reduction in bone strength and increased risk of fractures, which are linked to considerable morbidity, mortality, and high healthcare burdens. Bisphosphonates are the most commonly used drugs to manage osteoporosis and they consequently reduce fracture risk. However, one of the clinical challenges is fear of side effects in patients who are using bisphosphonates as the administration of these drugs is lengthy. Ocular inflammation has been reporting as one of the potential vision-threatening side effects of bisphosphonates.
OBJECTIVE: To review previously reported ocular inflammation in patients taking bisphosphonates.
METHODS: A literature survey was conducted using databases in order to collect data for a narrative review of published reports regarding ocular side effects of bisphosphonates.
RESULTS: People taking bisphosphonates were at a relatively low risk of ocular inflammation, with the onset from a few hours after exposure up to more than 3 years. The release of inflammatory mediators mainly by activated gamma delta T cells in response to bisphosphonates was the main cause of ocular inflammation.
CONCLUSIONS: Strategies for treating patients with osteoporosis should consider the potential ocular side effects of bisphosphonates. Ocular inflammation, as one of the side effects of bisphosphonates, is a serious sight-threatening sign and should be taken seriously. Greater awareness of the association between bisphosphonate use and ocular inflammation may allow for earlier identification and timely treatment of future cases.